✦ LIBER ✦

Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer

✍ Scribed by Matthew R Smith; Fred Saad; Blair Egerdie; Paul Sieber; Teuvo LJ Tammela; Benjamin Z Leder; Chunlei Ke; Carsten Goessl

Publisher: American Society for Bone and Mineral Research
Year: 2011
Tongue: English
Weight: 127 KB
Volume: 26
Category: Article
ISSN: 0884-0431
DOI: 10.1002/jbmr.492

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Androgen deprivation therapy (ADT) for prostate cancer increases fracture risk, decreases bone mineral density, and increases bone turnover markers (BTMs) including serum type 1 C‐telopeptide (sCTX), tartrate‐resistant alkaline phosphatase 5b (TRAP‐5b), and procollagen‐1 N‐terminal telopeptide (P1NP). In a prespecified exploratory analysis of a phase 3, multicenter, double‐blind study, we evaluated the effects of denosumab (60 mg subcutaneously every 6 months for 3 years) versus placebo (1468 patients, 734 in each group) on BTM values. BTMs were measured at baseline, month 1, and predose at months 6, 12, 24, and 36 in the overall population. BTMs at month 1 are also reported for subgroups based on age (< 70 years versus ≥ 70 years), prior duration of ADT (≤ 6 months versus >6 months), and baseline BTM (≤ median versus > median BTM values). Treatment with denosumab provided a rapid and sustained decrease of BTM values compared with placebo. The median change in sCTX levels at month 1 was −90% in the denosumab group and −3% in the placebo group (p < 0.0001). The median change in TRAP‐5b levels at month 1 was −55% in the denosumab group and −3% in the placebo group (p < 0.0001). The maximal median change in P1NP was −64% in the denosumab group and −11% in the placebo group, (p < 0.0001). Significantly greater decreases in BTM for denosumab were also seen in subgroup analyses based on age, prior ADT treatment, and baseline BTM values. Suppression of bone turnover markers was consistent with marked increases in bone mineral density reported previously. © 2011 American Society for Bone and Mineral Research

📜 SIMILAR VOLUMES

Pathologic changes associated with andro

Pathologic changes associated with androgen deprivation therapy for prostate cancer

✍ William M. Murphy; Mark S. Soloway; George H. Barrows 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 934 KB

Prostate glands exposed to androgen deprivation with leuprolide -+ flutamide were evaluated for pathologic changes which might be related to therapy. Comparing pretreatment and posttreatment tissue by visual discrimination using light microscopic study revealed treatment-related alterations in the s

Predictors of mortality after androgen-d

Predictors of mortality after androgen-deprivation therapy in patients with rapidly rising prostate-specific antigen levels after local therapy for prostate cancer

✍ Neesha A. Rodrigues; Ming-Hui Chen; William J. Catalona; Kimberly A. Roehl; Jero 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 156 KB 👁 2 views

The effect of combined androgen blockade

The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma : Longitudinal evaluation and response to intermittent cyclic etidronate therapy

✍ Terrence Diamond; Joanne Campbell; Carl Bryant; William Lynch 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB 👁 2 views

## BACKGROUND. Androgen receptor blocking agents have become an established form of therapy for men with disseminated prostate carcinoma. The purpose of this study was to evaluate markers of bone turnover and to measure bone mineral densities (BMD) in men with disseminated prostate carcinoma treat

Inhibition of the Akt, cyclooxygenase-2,

Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: Potential therapeutic approaches for prostate cancer

✍ Hiroshi Miyamoto; Saleh Altuwaijri; Yi Cai; Edward M. Messing; Chawnshang Chang 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB

## Abstract Prostate cancer cells are generally dependent on androgen stimulation mediated by the androgen receptor (AR) for growth and survival, and, therefore, hormonal manipulation, such as castration and/or the use of AR antagonists, results in a regression of the cancer. However, this treatmen

Pretreatment prostate-specific antigen v

Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy

✍ David Palma; Scott Tyldesley; Tom Pickles; for the Prostate Cohort Outcomes Init 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 135 KB 👁 1 views

## Abstract ## BACKGROUND In men with prostate cancer, pretreatment prostate‐specific antigen (PSA) velocity (PSAV) has been demonstrated as a predictor of biochemical and survival outcomes in patients undergoing radical prostatectomy (RP). The utility of pretreatment PSAV in predicting outcomes a

Krupski TL, Smith MR, Lee WC, et al. Nat

Krupski TL, Smith MR, Lee WC, et al. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy. Cancer. 2004;101(3):541–9.

📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 26 KB 👁 1 views

## Abstract The original article to which this Erratum refers was published in Cancer (2004) 101(3):541–9